sym015 shows superior specificity compared to tkis for nsclc
Published 4 years ago • 9 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
9:00
nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
-
0:59
sym015: met antibody mixture for advanced solid tumors
-
6:45
anti-pd1 or tyrosine kinase inhibitors?
-
2:25
dr. sweet discusses tki discontinuation in cml
-
4:28
brigatinib for nsclc, latest research and overcoming complications
-
3:26
sugemalimab plus platinum-based chemotherapy for metastatic non-small-cell lung cancer
-
0:44
com503: the next steps in harnessing cytokines to treat cancer
-
2:02
tki and checkpoint inhibitor combinations for kidney cancer: the immotion151 trial
-
1:55
what is the difference between limited stage and extensive stage small cell lung cancer?
-
2:26
additional egfr-tki therapy research in nsclc
-
3:24
2018 lung cancer update for clinicians by the cap-iaslc-amp
-
2:40
limited-stage sclc: is immunotherapy an option?
-
34:55
harnessing cytokines for cancer immunotherapy symposium: dr jamie spangler, johns hopkins university
-
4:10
case 3: extensive-stage sclc
-
5:00
breast cancer: identification & pharmacologic management of high-risk patients
-
8:01
response monitoring of patients with cml treated with tkis
-
9:52
factors in selecting immunotherapy or tki inhibition
-
4:23
treatment approach in limited- and extensive-stage sclc
-
20:15
response criteria and kinetics with immunocheckpoint inhibitors